Saheli Datta
Biographic Data
| ID | 3919792 |
|---|---|
| NAME | Saheli Datta |
| GIVEN NAMES | Saheli |
| FAMILY NAME | Datta |
| SIGNATURE | DATTA S |
| AFFILIATIONS | King's College London |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 16 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2015 |
| LATEST PUBLICATION YEAR | 2016 |
| H-INDEX | 2 |
Governing new global health-care markets: The case of stem cell treatments
Stem cell innovation has enabled the growth of a global market of treatments for a wide range of diseases but most of this market operates outside the domain of orthodox forms of innovation governance. Much of the analysis of this issue has adopted a supply side perspective informed by the values of the orthodox scientific model of biomedical innovation, arguing that national and transnational regulation has failed to impose appropriate standards…
Bioinformatics and the Politics of Innovation in the Life Sciences: Science and the State in the United Kingdom, China, and India
The governments of China, India, and the United Kingdom are unanimous in their belief that bioinformatics should supply the link between basic life sciences research and its translation into health benefits for the population and the economy. Yet at the same time, as ambitious states vying for position in the future global bioeconomy they differ considerably in the strategies adopted in pursuit of this goal. At the heart of these differences lies…
Hegemony in the marketplace of biomedical innovation: Consumer demand and stem cell science
The global political economy of stem cell therapies is characterised by an established biomedical hegemony of expertise, governance and values in collision with an increasingly informed health consumer demand able to define and pursue its own interest. How does the hegemony then deal with the challenge from the consumer market and what does this tell us about its modus operandi? In developing a theoretical framework to answer these questions, the…
Hegemony in the marketplace of biomedical innovation: Consumer demand and stem cell science
The global political economy of stem cell therapies is characterised by an established biomedical hegemony of expertise, governance and values in collision with an increasingly informed health consumer demand able to define and pursue its own interest. How does the hegemony then deal with the challenge from the consumer market and what does this tell us about its modus operandi? In developing a theoretical framework to answer these questions, the…
Governing new global health-care markets: The case of stem cell treatments
Stem cell innovation has enabled the growth of a global market of treatments for a wide range of diseases but most of this market operates outside the domain of orthodox forms of innovation governance. Much of the analysis of this issue has adopted a supply side perspective informed by the values of the orthodox scientific model of biomedical innovation, arguing that national and transnational regulation has failed to impose appropriate standards…
Bioinformatics and the Politics of Innovation in the Life Sciences: Science and the State in the United Kingdom, China, and India
The governments of China, India, and the United Kingdom are unanimous in their belief that bioinformatics should supply the link between basic life sciences research and its translation into health benefits for the population and the economy. Yet at the same time, as ambitious states vying for position in the future global bioeconomy they differ considerably in the strategies adopted in pursuit of this goal. At the heart of these differences lies…
Hegemony in the marketplace of biomedical innovation: Consumer demand and stem cell science
The global political economy of stem cell therapies is characterised by an established biomedical hegemony of expertise, governance and values in collision with an increasingly informed health consumer demand able to define and pursue its own interest. How does the hegemony then deal with the challenge from the consumer market and what does this tell us about its modus operandi? In developing a theoretical framework to answer these questions, the…
Governing new global health-care markets: The case of stem cell treatments
Stem cell innovation has enabled the growth of a global market of treatments for a wide range of diseases but most of this market operates outside the domain of orthodox forms of innovation governance. Much of the analysis of this issue has adopted a supply side perspective informed by the values of the orthodox scientific model of biomedical innovation, arguing that national and transnational regulation has failed to impose appropriate standards…
Bioinformatics and the Politics of Innovation in the Life Sciences: Science and the State in the United Kingdom, China, and India
The governments of China, India, and the United Kingdom are unanimous in their belief that bioinformatics should supply the link between basic life sciences research and its translation into health benefits for the population and the economy. Yet at the same time, as ambitious states vying for position in the future global bioeconomy they differ considerably in the strategies adopted in pursuit of this goal. At the heart of these differences lies…
Economics (3 works) · Political science (3 works) · Politics (3 works) · Biomedical Ethics and Regulation (2 works) · Biotechnology and Related Fields (2 works) · Law (2 works) · Social science (2 works) · Sociology (2 works) · Agency (philosophy (1 works) · Argument (complex analysis (1 works)